Patent ID: 8388958
Filing Date: 2013-03-05
Classification: A61K,A61P,C07K,C12N

Abstract:
1. A method of treating a tumor or tumor metastases comprising administering to a patient in need thereof: i) the anti-Met monoclonal antibody AntiMET-R, ii) a fragment containing the epitope binding region of the anti-Met monoclonal antibody AntiMET-R or iii) a genetically engineered antibody containing the complementarity determining regions (CDRs) of the anti-Met monoclonal antibody AntiMET-R, wherein CDR-H1 is SEQ ID NO.:8, CDR-H2 is SEQ ID NO.:9, CDR-H3 is SEQ ID NO.:10, CDR-L1 is SEQ ID NO.:11, CDR-L2 is SEQ ID NO.:12 and CDR-L3 is SEQ ID NO.:13 in an amount sufficient to effect said treatment, wherein said antibody AntiMET-R is produced by the hybridoma cell line ICLC PD 05006.